IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 7390833 B1

PDFFull Text
Date of Patent:
Jun. 24, 2008

Filed:

Nov. 08, 2004

Method for treating adamts-5-associated disease

Applicants:

Elisabeth A. Morris, Sherborn, MA (US);

Sonya Glasson, Belmont, MA (US);

Jason Shaoyun Xiang, Winchester, MA (US);

Inventors:

Elisabeth A. Morris, Sherborn, MA (US);

Sonya Glasson, Belmont, MA (US);

Jason Shaoyun Xiang, Winchester, MA (US);

Assignee:

Wyeth, Madison, NJ (US);

Attorney:

Fitzpatrick, Cella, Harper & Scinto

Primary Examiner:

Ardin Marschel

Assistant Examiner:

Amy A Lewis

Int. Cl.
CPC ...
A01N 41/02 (2006.01); A01N 37/34 (2006.01); A01N 37/30 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 31/275 (2006.01); A61K 31/205 (2006.01); A61K 31/195 (2006.01); A61K 31/255 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.

Find Patent Forward Citations

Loading…